← Back

Siemens Healthineers AG

Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers in Germany, the United States, rest of Europe, CIS, Africa, the Middle East, the Americas, the Asia Pacific, Japan, and China. It operates in four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment offers magnetic resonance imaging, computed tomography, X-ray, molecular imaging, and ultrasound systems; and software solutions to support the reading and structured reporting of diagnostic images from different modalities. Its Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in the fields of general and specialty laboratory, and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment offers microwave, cryoablation, and embolization technologies, as well as clinical professional services for cancer care that support oncology departments in hospitals and clinics; and customized support for cancer care operations. Its Advanced Therapies segment provides products that are designed to support image-guided minimally invasive clinical procedures in various areas, such as cardiology, neurology, and oncology; angiography systems and mobile C-arms; and AI-powered clinical applications. It also offers essential technical customer service, such as maintenance and repair; spare parts; medical equipment performance management; training; clinical education and e-learning; planning and design; financing; asset management; and managed departmental services for laboratories and healthcare facilities, as well as healthcare consulting, products, and services. It has strategic partnership with IFS to increase product lifecycle with industrial AI. The company was founded in 1896 and is headquartered in Forchheim, Germany. Siemens Healthineers AG is a subsidiary of Siemens Aktiengesellschaft.

Price · split & dividend adjusted
News & notes moving SHL.XETRA
Artificial Intelligence

Global AI in Medical Imaging Market to Reach USD 19.4 Billion by 2035

The global AI in medical imaging market is projected to grow from USD 2.9 billion in 2025 to USD 19.4 billion by 2035, at a compound annual growth rate of 20.9%, according to a new report by Healthcare Foresights. The market is expected to reach USD 3.5 billion in 2026, driven by a shortage of radiologists, high imaging volumes, and the need for faster clinical decision-making. Key growth factors include advancements in deep learning algorithms, increasing adoption of digital health technologies, and supportive regulatory approvals for AI-powered tools. North America is forecast to grow at a CAGR of 16.7%, while the Asia Pacific region is experiencing the highest growth due to rapid digital health transformation and expanding medical imaging infrastructure. Prominent players in the market include GE HealthCare Technologies, Siemens Healthineers, Koninklijke Philips, and Canon Medical Systems.
GlobeNewswire·22dRead more ▾
Biotech & Genomic Medicine

Siemens Healthineers Trades at 19.3% Discount to Fair Value After Mixed Earnings Update

Siemens Healthineers reported third quarter and nine month 2026 earnings alongside updated guidance that lowered its revenue outlook but raised its adjusted earnings forecast. The stock has gained 5.13% over the past seven days and 6.90% over the past 30 days, yet it remains down 16.49% year to date and has posted an 18.70% decline in total shareholder return over the past year. Against a last close of €36.86, the most followed narrative sets the company's fair value at €45.65, implying a 19.3% undervaluation. The bullish case rests on accelerating digital and AI adoption in healthcare, a growing installed base of automated diagnostic platforms, and emerging market infrastructure investments, while risks include tariff pressures and pricing reforms in China that could weigh on margins.
Simply Wall St·24dRead more ▾
SHL.XETRA

Siemens Healthineers lifts fiscal 2026 earnings view but cuts revenue growth outlook

Siemens Healthineers raised its fiscal 2026 adjusted earnings per share forecast while lowering its comparable revenue growth outlook. The company now expects adjusted basic earnings per share between €2.35 and €2.45, up from the prior range of €2.20 to €2.30, and comparable revenue growth of 3.5 percent to 4.0 percent, down from 4.5 percent to 5.0 percent. The revision reflects the performance of the Diagnostics segment and the impact of tariff refunds under the U.S. International Emergency Economic Powers Act. Third-quarter net income rose to €669 million from €552 million a year earlier, with adjusted EBIT climbing 15.6 percent to €1.101 billion and revenue increasing 1.8 percent to €5.764 billion.
RTTNews·27dRead more ▾
SHL.XETRA

Siemens Healthineers Appoints João Seabra President and Head of the Americas

Siemens Healthineers has appointed João Seabra as President and Head of the Americas, effective October 1, 2026, succeeding John Kowal. Seabra currently leads the company's Enterprise Services unit, where he quadrupled revenue over the past eight years. He joined Siemens Healthineers in 2001 and previously led the Western Europe and West Africa regions. Darleen Caron, Member of the Managing Board and Chief Human Resources Officer, praised Seabra's international leadership experience and customer focus, calling him the ideal candidate to lead the Americas, the company's largest market. Seabra holds a master's degree in computer and electric engineering from Universidade do Porto and will relocate from Portugal to the United States.
GlobeNewswire·27dRead more ▾
SHL.XETRA

Siemens Healthineers Survey Finds Healthcare Executives Prioritize Lab Upgrades Just Behind AI

A new survey commissioned by Siemens Healthineers and conducted by YouGov finds that 82% of U.S. healthcare executives considered expanding their laboratory services in the past year, and 54% are prioritizing diagnostic and lab equipment upgrades, second only to AI tools. The findings, released at the ADLM 2026 Annual Scientific Meeting, show that 81% of the 155 surveyed executives strongly agree lab turnaround times directly affect patient care, and 72% strongly agree lab performance is critical to wider organizational efficiency. However, the survey also reveals that 31% of executives whose lab investment considerations stalled cited uncertainty about the cost-benefit proposition as the primary reason, highlighting an opportunity to make clearer business cases for laboratory modernization.
GlobeNewswire·29dRead more ▾
Biotech & Genomic Medicine2

Radiotherapy Market to Reach USD 10.68 Billion by 2031 at 6.0% CAGR

The global radiotherapy market is projected to grow from USD 7.98 billion in 2026 to USD 10.68 billion by 2031, at a CAGR of 6.0%, according to a new report by MarketsandMarkets. Growth is driven by rising cancer incidence, increased healthcare investments, and demand for precision oncology, with rapid adoption of technologies such as proton beam therapy, adaptive radiotherapy, and AI-based treatment planning. The systems segment is expected to hold the largest share, while external beam radiotherapy dominates across technology, application, and procedure segments, and hospitals remain the leading end user. Asia Pacific is forecast to register the highest CAGR, supported by expanding oncology infrastructure and government spending in countries including China, India, and Japan. Key players include Siemens Healthineers AG, Elekta, Accuray Incorporated, IBA Worldwide, and ViewRay Technologies.
GlobeNewswire·35dRead more ▾
Artificial Intelligence2

United Imaging Intelligence resists aggressive AI rollout, says co-CEO

United Imaging Intelligence, an AI-focused subsidiary of Chinese medical technology giant Shanghai United Imaging Healthcare, is taking a cautious approach to deploying AI tools, resisting pressure for an aggressive rollout. Co-CEO Zhou Xiang, speaking on the sidelines of the World Artificial Intelligence Conference, said the company is not that extreme, noting that software engineers and architects warned him about potential side effects because the technology remains insufficiently mature. He added that in healthcare and medicine, the first mover advantage is not as drastic as in other fields. The United Imaging group competes with GE HealthCare, Siemens Healthineers and Philips in medical imaging and scanning equipment.
Reuters·37dRead more ▾
SHL.XETRA

Roche Launches First Fully Automated High-Throughput Hepatitis D Test

Roche Holding has introduced the cobas HDV test, the first fully automated, high-throughput assay for Hepatitis D Virus detection. The test targets a major unmet clinical need for improved diagnosis and monitoring of the most aggressive form of viral hepatitis, and is designed to support laboratories as new HDV treatments become available. It runs on existing cobas 5800, 6800, and 8800 systems, allowing labs to add HDV testing without major new capital spending. An estimated 12 million people globally have HDV, and the launch may strengthen Roche's installed-base relevance against diagnostics competitors such as Abbott and Siemens Healthineers. Investors will watch adoption rates, reimbursement decisions, and future disclosures on hepatitis assay contributions within Roche's virology portfolio.
Simply Wall St·42dRead more ▾
Artificial Intelligence

AI in Ultrasound Imaging Market to Reach $2.23 Billion by 2030

The global AI in ultrasound imaging market is projected to grow from $1.28 billion in 2025 to $2.23 billion by 2030, at a compound annual growth rate of 11.8%. This growth is driven by increasing demand for point-of-care diagnostics, advancements in machine learning algorithms, and the rising prevalence of cancer. Key players include Samsung Electronics, Intel Corporation, IBM, NVIDIA, and Siemens Healthineers, which launched the portable AI-powered Acuson Maple system in November 2023. GE HealthCare strengthened its ultrasound offerings through the acquisition of Caption Health in February 2023. North America led the market in 2025, while Asia-Pacific is expected to witness the fastest growth during the forecast period.
GlobeNewswire·50dRead more ▾
Artificial Intelligence

AI Investment in Medical Plastics Surges Past $2.3 Billion in 2024

Investment in artificial intelligence for the medical plastics market surged past $2.3 billion in 2024, according to BCC Research. BASF led the spending with a $1.1 billion research and development commitment to AI reactor technology. The European Commission approved $471 million in public funding for medical device AI innovation, while Siemens Healthineers secured a $560 million AI deal with the Canadian government. Key players including Medtronic, Johnson & Johnson, Abbott Laboratories, and Boston Scientific are also driving AI integration to enhance manufacturing precision and quality control.
BCC Research·55dRead more ▾
Robotics & Physical AI

CISCE Healthy Life Chain Showcases Global Healthcare Supply Chain Innovation

The Fourth China International Supply Chain Expo has opened its Healthy Life Chain section, drawing more than 100 leading companies across Medical Technology, Quality Living, and Heritage Wellness zones. Global players GE Healthcare and Siemens Healthineers are demonstrating full China-for-China R&D and manufacturing capabilities, while AstraZeneca features an AI-powered drug discovery platform. Chinese innovators including BGI with a human genome foundation model and Longwood Valley with a domestically produced orthopedic surgical robot are also taking center stage. In consumer health, Procter & Gamble, L'Oréal, Panasonic, and Starbucks are showcasing digital intelligence and sustainability in their supply chains, with Starbucks connecting directly to Yunnan coffee farms for full traceability. Chinese TCM brands such as Guangzhou Phar. Holdings, Xin Bao Tang, and Zhendong Pharmaceutical are accelerating global expansion and vertical integration of authentic herb supply chains, alongside AI-driven diagnostic tools like smart pulse-taking devices.
PR Newswire·62dRead more ▾
Robotics & Physical AIimpact 4

NVIDIA Launches Public Beta of XR AI Framework for AR Glasses and XR Devices

NVIDIA has released NVIDIA XR AI in public beta, a framework for building multimodal AI agents for AR glasses and XR devices. The release extends NVIDIA's AI infrastructure beyond hyperscale training clusters into edge and physical AI, connecting XR device inputs with models, enterprise data, tools, and accelerated computing. It integrates services such as Metropolis, NeMo Retriever, Nemotron, Cosmos Reason, and DGX/RTX PRO systems. Early use cases include Siemens factory maintenance research, lab workflows from Rana's LabOS, and surgical-assistance work at UPMC. NVIDIA reported fiscal Q1 2027 revenue of $81.6 billion, up 85% year-over-year, with data center revenue rising 92% to $75.2 billion.
Insider Monkey·68dRead more ▾
SHL.XETRA

Healthcare Command Centers Market to Reach USD 5.0 Billion by 2034

The global healthcare command centers market is projected to grow from USD 1.8 billion in 2024 to USD 5.0 billion by 2034, at a compound annual growth rate of 10.8%, according to a new report from Zion Market Research. The software component segment held a 48% share in 2024, while the cloud-based deployment mode accounted for 49% of the market. North America led with a 41% share, driven by advanced healthcare infrastructure and technology adoption. Key players include GE HealthCare, Koninklijke Philips N.V., Siemens Healthineers, and Oracle (Cerner).
GlobeNewswire·69dRead more ▾